Rev Med Virol. 2006 Mar-Apr;16(2):117-31.

Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.

Tsunetsugu-Yokota Y, Ohnishi K, Takemori T.

Source

Department of Immunology, National Institute of Infectious Diseases, Toyama-cho, Shinjuku-ku, Tokyo, Japan.

Abstract

SARS-CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS-CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS-CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future.

2006 John Wiley & Sons, Ltd.

PMID:: 16518829; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Severe Acute Respiratory Syndrome - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. [Curr Opin Mol Ther. 2005]
Review Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.
Zhang MY, Choudhry V, Xiao X, Dimitrov DS. Curr Opin Mol Ther. 2005 Apr; 7(2):151-6.
Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. [Clin Vaccine Immunol. 2009]
Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.
Lu B, Tao L, Wang T, Zheng Z, Li B, Chen Z, Huang Y, Hu Q, Wang H. Clin Vaccine Immunol. 2009 Jan; 16(1):73-7. Epub 2008 Nov 5.
Review Vaccine design for severe acute respiratory syndrome coronavirus. [Viral Immunol. 2005]
Review Vaccine design for severe acute respiratory syndrome coronavirus.
He Y, Jiang S. Viral Immunol. 2005; 18(2):327-32.
Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. [J Gen Virol. 2008]
Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
See RH, Petric M, Lawrence DJ, Mok CP, Rowe T, Zitzow LA, Karunakaran KP, Voss TG, Brunham RC, Gauldie J, et al. J Gen Virol. 2008 Sep; 89(Pt 9):2136-46.
Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. [Immunology. 2007]
Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice.
Lu X, Chen Y, Bai B, Hu H, Tao L, Yang J, Chen J, Chen Z, Hu Z, Wang H. Immunology. 2007 Dec; 122(4):496-502. Epub 2007 Aug 3.

See reviews... See all...

Cited by 1 PubMed Central article

Review Progress towards recombinant anti-infective antibodies. [Recent Pat Antiinfect Drug Dis...]
Review Progress towards recombinant anti-infective antibodies.
Pai JC, Sutherland JN, Maynard JA. Recent Pat Antiinfect Drug Discov. 2009 Jan; 4(1):1-17.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal ...
Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Rev Med Virol. 2006 Mar-Apr ;16(2):117-31.

PubMed
Geographic differences in antimalarial drug efficacy in Uganda are explained by ...
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance.
J Infect Dis. 2006 Apr 1 ;193(7):978-86. Epub 2006 Mar 1 .

PubMed
Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myelo...
Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma.
Mamm Genome. 2006 Mar ;17(3):248-56. Epub 2006 Mar 3 .

PubMed
Structure-activity relationships of the delta-opioid-selective agonists, deltorp...
Structure-activity relationships of the delta-opioid-selective agonists, deltorphins.
Eur J Pharmacol. 1991 Mar 26 ;195(2):201-7.

PubMed
Local cell proliferation in rheumatoid synovial tissue: analysis by cyclin expre...
Local cell proliferation in rheumatoid synovial tissue: analysis by cyclin expression.
Clin Rheumatol. 2006 Nov ;25(6):801-6. Epub 2006 Mar 2 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: